Suppr超能文献

共价泛磷脂酰肌醇5-磷酸4-激酶抑制剂的构效关系研究

Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.

作者信息

Manz Theresa D, Sivakumaren Sindhu C, Yasgar Adam, Hall Matthew D, Davis Mindy I, Seo Hyuk-Soo, Card Joseph D, Ficarro Scott B, Shim Hyeseok, Marto Jarrod A, Dhe-Paganon Sirano, Sasaki Atsuo T, Boxer Matthew B, Simeonov Anton, Cantley Lewis C, Shen Min, Zhang Tinghu, Ferguson Fleur M, Gray Nathanael S

机构信息

Department of Cancer Biology, Dana-Farber Cancer Institute, 360 Longwood Avenue, Boston, Massachusetts 02215, United States.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.

出版信息

ACS Med Chem Lett. 2019 Nov 3;11(3):346-352. doi: 10.1021/acsmedchemlett.9b00402. eCollection 2020 Mar 12.

Abstract

Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are important molecular players in a variety of diseases, such as cancer. Currently available PI5P4K inhibitors are reversible small molecules, which may lack selectivity and sufficient cellular on-target activity. In this study, we present a new class of covalent pan-PI5P4K inhibitors with potent biochemical and cellular activity. Our designs are based on THZ-P1-2, a covalent PI5P4K inhibitor previously developed in our lab. Here, we report further structure-guided optimization and structure-activity relationship (SAR) study of this scaffold, resulting in compound , which retained biochemical and cellular potency, while demonstrating a significantly improved selectivity profile. Furthermore, we confirm that the inhibitors show efficient binding affinity in the context of HEK 293T cells using isothermal CETSA methods. Taken together, compound represents a highly selective pan-PI5P4K covalent lead molecule.

摘要

磷脂酰肌醇5-磷酸4-激酶(PI5P4K)是多种疾病(如癌症)中的重要分子参与者。目前可用的PI5P4K抑制剂是可逆的小分子,可能缺乏选择性和足够的细胞靶向活性。在本研究中,我们提出了一类具有强大生化和细胞活性的新型共价泛PI5P4K抑制剂。我们的设计基于THZ-P1-2,这是我们实验室之前开发的一种共价PI5P4K抑制剂。在此,我们报告了对该支架的进一步结构导向优化和构效关系(SAR)研究,得到了化合物 ,其保留了生化和细胞活性,同时显示出显著改善的选择性。此外,我们使用等温CETSA方法证实了这些抑制剂在HEK 293T细胞环境中显示出有效的结合亲和力。综上所述,化合物 代表了一种高度选择性的泛PI5P4K共价先导分子。

相似文献

2
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.使用共价抑制剂靶向癌症中的PI5P4K脂质激酶家族。
Cell Chem Biol. 2020 May 21;27(5):525-537.e6. doi: 10.1016/j.chembiol.2020.02.003. Epub 2020 Mar 3.
5
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.鉴定ARUK2002821为一种亚型选择性PI5P4Kα抑制剂。
RSC Med Chem. 2023 Apr 17;14(5):934-946. doi: 10.1039/d3md00039g. eCollection 2023 May 25.
7
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.新型强效 GSK-3β 抑制剂 AF3581 的稳定情绪作用。
Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26.
8
Structure and Characterization of a Covalent Inhibitor of Src Kinase.Src激酶共价抑制剂的结构与表征
Front Mol Biosci. 2020 May 19;7:81. doi: 10.3389/fmolb.2020.00081. eCollection 2020.

引用本文的文献

3
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.鉴定ARUK2002821为一种亚型选择性PI5P4Kα抑制剂。
RSC Med Chem. 2023 Apr 17;14(5):934-946. doi: 10.1039/d3md00039g. eCollection 2023 May 25.
4
Development of potent and selective degraders of PI5P4Kγ.开发高效且选择性的 PI5P4Kγ 降解剂。
Eur J Med Chem. 2023 Feb 5;247:115027. doi: 10.1016/j.ejmech.2022.115027. Epub 2022 Dec 24.
6
Beyond PI3Ks: targeting phosphoinositide kinases in disease.超越 PI3Ks:疾病中磷酸肌醇激酶的靶向治疗。
Nat Rev Drug Discov. 2023 May;22(5):357-386. doi: 10.1038/s41573-022-00582-5. Epub 2022 Nov 14.
10
Mechanistic roles of mutant p53 governing lipid metabolism.突变型 p53 调控脂代谢的机制作用。
Adv Biol Regul. 2022 Jan;83:100839. doi: 10.1016/j.jbior.2021.100839. Epub 2021 Nov 23.

本文引用的文献

1
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.使用共价抑制剂靶向癌症中的PI5P4K脂质激酶家族。
Cell Chem Biol. 2020 May 21;27(5):525-537.e6. doi: 10.1016/j.chembiol.2020.02.003. Epub 2020 Mar 3.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验